Peptide Drug Conjugates Market Size, Trends, Share, Growth | Report 2022-2030
The next next-generation drug target therapeutics, Peptide Drug Conjugates (PDCs) deliver cytotoxic drugs to the target tissue, with the core advantage of improved permeability, drug selectivity, and reduced toxicity. Peptide The peptide drug conjugates market has provided a new channel to targeted therapy, thereby delivering new clinical opportunities that were lacking in traditional cancer treatment.
Currently, the space has two FDA FDA-approved PDCs, Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. In February 2021, FDA granted accelerated approval to Pepaxto (Melphalan flufenamide) in combination with dexamethasone, indicated for multiple myeloma in adult patients. However,Oncopeptides AB’s Pepaxto is temporarily withdrawn from the US market due to inferior overall survival results in phase 3 trials. Before that, FDA FDA-approved PDC was Novartis’s Lutathera (lutetium Lu 177), indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Thus, the limited innovation in the space is offering lucrative opportunity opportunities for market growth.
Peptide drug conjugates market has been segmented on the basis ofbased on product as follows:
The robust clinical trial pipeline and increasing investment in R&D is leading to the development of peptide drug conjugates. Therefore, it is expected that in the coming years, there will be rapid approval of many new PDCs in the treatment of multiple types of cancer. For instance, currently, AngioChem, Inc.’s ANG1005 to treat a brain tumor, is in phase 3 clinical investigation. Similarly, Bicycle therapeutics’ BT1718, and BT5528 are in phase 1or 2 clinical stages for non-small cell carcinoma. Thus, space is anticipated to offer growth over the forthcoming years.
The recent advancement in peptide drug conjugate space has grabbed the interest of pharma companies. Therefore, rising strategic initiatives such as collaborations & mergers, partnerships, and financial investments by key market players is fueling the market growth. For instance, PeptiDream Inc. and Novartis AG collaborated to develop PDC, a macrocyclic peptide for therapeutic and diagnostic applications.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Peptide Drug Conjugates Market
5.1. COVID-19 Landscape: Peptide Drug Conjugates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Peptide Drug Conjugates Market, By Product
8.1. Peptide Drug Conjugates Market, by Product, 2022-2030
8.1.1. Lutetium
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Melflufen
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. ANG1005
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. BT1718
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. CBX-12
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Pipeline Products
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Peptide Drug Conjugates Market, By Type
9.1. Peptide Drug Conjugates Market, by Type, 2022-2030
9.1.1. Diagnostic
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Therapeutic
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Peptide Drug Conjugates Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Type (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Type (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Type (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Type (2017-2030)
Chapter 11. Company Profiles
11.1. Bicycle Therapeutics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cybrexa Therapeutics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Oncopeptides Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Pepgen Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Innovasium Soricimed Biopharma
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Theratechnologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Esperance Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers